Pancreatic cancer is a deadly disease. It has the highest mortality rate among all cancers and is the fifth-leading cause of cancer death in Australia. Nearly 4,000 Australians were diagnosed with pancreatic cancer in 2020 and more than 3,000 died. Although survival for many types of cancer has improved, pancreatic cancer has only marginally improved. The disease is extremely hard to treat because it is often not diagnosed until a late stage.
What does the pancreas do?
What are the risk factors of pancreatic cancer?
Pancreatic cancer diagnosis
Our pancreatic cancer research
While survival for many types of cancer has improved in the last 40 years, the high mortality and poor survival rates for pancreatic cancer have only marginally improved. Our scientists are studying how this deadly cancer develops to find new ways to save lives through earlier diagnoses and new treatments. They are doing this by identifying regulators of the immune system that drive pancreatic cancer, and thus serve as new biomarkers and therapeutic targets for immune-based treatments.
Precision medicine for pancreatic cancer
Targeted treatment. In collaboration with Dr Daniel Croagh, a leading Monash Health pancreatic surgeon, Professor Brendan Jenkins has co-developed a new protocol to genetically screen virtually all pancreatic cancer patients for specific mutations in their tumours and targeting with specific drugs (precision medicine). This is a substantial improvement on previous genetic screening protocols which could only screen tumours from about 20 per cent of early-stage disease patients who were eligible for surgery.
This discovery means that many more pancreatic cancer patients can be screened for targeted therapy with specific drugs based on their own personalised tumour profile and has laid the groundwork for a clinical trial with Dr Croagh aimed at improving pancreatic cancer survival rates.
Identifying the role of TLR2 in pancreatic cancer
Cancer and inflammation
Pancreatic cancer news
Big benefits in detection and treatment of pancreatic cancer
Researchers receive collaboration grant from PanKind to expand targeted screening for pancreatic cancer
Pancreatic cancer funding boost
Mistaken identity: new mechanism behind stomach cancer identified
NHMRC Fellowship success
Harnessing immune therapies to combat pancreatic cancer
Precision medicine pipeline may improve drug treatment for pancreatic cancer
CASS Foundation supports three Hudson Institute research projects
See more news articles about Pancreatic cancer
Pancreatic cancer collaborators
Support for people with pancreatic cancer
Hudson Institute scientists cannot provide medical advice.
Find out more about Pancreatic cancer.
Keep up-to-date with our latest discoveries